Eur Rev Med Pharmacol Sci 2019; 23 (16): 6849-6857

DOI: 10.26355/eurrev_201908_18724

DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer

H.-F. Zhao, Z.-C. Zhang, B.-K. Shi, X.-Z. Jiang

Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong. 18560083909@163.com


OBJECTIVE: Paclitaxel is one of the most common drugs for cancer treatment. LncRNA DANCR is a regulator of up-regulation in tumors. Our experiment aims to clarify the role of DANCR in paclitaxel sensitivity of prostate cancer.

PATIENTS AND METHODS: We found that the expression of DANCR in prostate cancer tissues and cells was significantly higher than that in normal groups. DANCR knockdown could reduce cell proliferation and induce cell apoptosis in cells. Moreover, DANCR silence enhanced the effect of paclitaxel on cell proliferation and apoptosis in prostate cancer cells.

RESULTS: DANCR targeted and negatively regulated the expression of miR-135a. miR-135a overexpression inhibited cell proliferation and promoted cell apoptosis and paclitaxel sensitivity in prostate cancer cells. miR-135a inhibition reversed the promoting effect of DANCR silence on paclitaxel sensitivity in prostate cancer cells.

CONCLUSIONS: Downregulation of DANCR increased paclitaxel sensitivity in prostate cancer cells by negatively regulating the expression of miR-135a.

Free PDF Download

To cite this article

H.-F. Zhao, Z.-C. Zhang, B.-K. Shi, X.-Z. Jiang
DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 16
Pages: 6849-6857
DOI: 10.26355/eurrev_201908_18724